Paion AG
OTC: PAIOF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Gregor Siebert
- Employees
- 64
- Headquarters
- Aachen, Germany
- IPO year
- 2009
- Market cap
- $75.3K
- Website
- https://www.paion.com
Loading PAIOF…
Loading profile data…Frequently asked questions about PAIOF
What does Paion AG (PAIOF) do?
Paion AG is a specialized biopharmaceutical company that operates globally, focusing on the development and commercialization of medications intended for hospital settings, specifically for sedation, anesthesia, and critical care management. Its primary product in development is Remimazolam, an ultra-short-acting intravenous benzodiazepine-class...
Where does PAIOF trade?
Paion AG (PAIOF) trades on the Other OTC.
What sector is PAIOF in?
Paion AG (PAIOF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Paion AG?
Gregor Siebert is the chief executive officer of Paion AG (PAIOF).
Where is Paion AG headquartered?
Paion AG is headquartered in Germany.
Does PAIOF pay a dividend?
Paion AG (PAIOF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PAIOF go public?
Paion AG (PAIOF) completed its initial public offering in 2009.